A Phase 2, Double-Blind, Placebo-Controlled, Double-Dummy, Cross-Over Study to Investigate the Hypnotic Activity of Three Doses (10mg, 15mg, 20mg) of a New Zaleplon Prototype, SKP-1041, in Adults With Primary Insomnia.
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2013
At a glance
- Drugs Zaleplon (Primary)
- Indications Sleep maintenance insomnia
- Focus Therapeutic Use
- 02 Jun 2011 Status changed from active, no longer recruiting to completed.
- 23 Mar 2011 Primary endpoint 'Wake-time-after-sleep-onset' has been met.
- 05 Nov 2010 Results data are expected to be unblinded in the first half of 2011, according to a Somnus therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History